Drug intelligence / Profile preview

MW189

Development stage: Phase 2
Lead developer: Tetra Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

MW189 is a brain-penetrant, small molecule inhibitor of p38α mitogen-activated protein kinase (p38α MAPK) designed to modulate neuroinflammation. Developed by Dr. D. Martin Watterson at Northwestern University and licensed to Transition Therapeutics (later acquired by OPKO Health), MW189 targets the overproduction of proinflammatory cytokines by glia. It has been evaluated in clinical trials for the treatment of acute brain injury and intracerebral hemorrhage (ICH), including the Phase 2a BEACH trial. The compound is distinguished by its selectivity for the p38α isoform and its ability to cross the blood-brain barrier, offering a potential therapeutic approach for both acute and chronic neurodegenerative conditions.

Other names: MW189MW-189MW 189

Targets

MAPK14 (p38 mitogen-activated protein kinase alpha)

Beyond the preview

Go deeper on MW189.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MW189.

Explore the full profile